
Fostair in COPD
- Fostair NEXThaler 100/6
- Fostair pMDI 100/6

- Fostair NEXThaler 100/6
- Fostair pMDI 100/6
Comparable efficacy
- Fostair NEXThaler has demonstrated comparable efficacy to Fostair pMDI across a variety of lung function measures1
- Both Fostair pMDI and Fostair NEXThaler are characterised by an extrafine particle size distribution1,2
Fostair‘s extrafine particle size distribution results in a more potent effect than formulations of beclometasone with a non-extrafine particle size distribution2
100mcg of extrafine beclometasone in Fostair is equivalent to 250mcg of non-extrafine beclometasone2
Click here for Fostair® (beclometasone/formoterol) Prescribing Information.
Fostair 100/6 is indicated for symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators.1,2
COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 second; pMDI: pressurised metered dose inhaler.
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.